WO2001054676A3 - Formulations for states of dehydration - Google Patents
Formulations for states of dehydration Download PDFInfo
- Publication number
- WO2001054676A3 WO2001054676A3 PCT/EP2001/000863 EP0100863W WO0154676A3 WO 2001054676 A3 WO2001054676 A3 WO 2001054676A3 EP 0100863 W EP0100863 W EP 0100863W WO 0154676 A3 WO0154676 A3 WO 0154676A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- creatine
- formulations
- dehydration
- states
- achieve
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 6
- 238000009472 formulation Methods 0.000 title abstract 5
- 230000018044 dehydration Effects 0.000 title abstract 4
- 238000006297 dehydration reaction Methods 0.000 title abstract 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 abstract 9
- 229960003624 creatine Drugs 0.000 abstract 4
- 239000006046 creatine Substances 0.000 abstract 4
- 208000005156 Dehydration Diseases 0.000 abstract 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 abstract 1
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 abstract 1
- 229940072107 ascorbate Drugs 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 239000011668 ascorbic acid Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 229960004826 creatine monohydrate Drugs 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000003978 infusion fluid Substances 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Formulations for dehydration states are disclosed, which comprise creatine and/or creatine derivatives, such as creatine monohydrate, creatine ascorbate, and creatine pyruvate and/or mixtures thereof, in such quantities that the creatine components do not exceed a daily dose of 4g of creatine. Said formulations which are, most notably, available in the form of infusion solutions and drinks, but also as tablets, capsules and powders, are used, preferably in patients with dehydration states caused, in particular, by age and/or immobility and/or by a disturbed fluid uptake. Said formulations can also be applied in the framework of an adjutant therapy in dehydration states. Said formulations achieve not just a better and increased water uptake in the various body tissues, but also achieve a significantly longer storage of water in the tissue.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2001244108A AU2001244108A1 (en) | 2000-01-28 | 2001-01-26 | Formulations for states of dehydration |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10003835A DE10003835A1 (en) | 2000-01-28 | 2000-01-28 | Formulations in dehydration conditions |
| DE10003835.2 | 2000-01-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2001054676A2 WO2001054676A2 (en) | 2001-08-02 |
| WO2001054676A3 true WO2001054676A3 (en) | 2002-05-16 |
Family
ID=7629123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2001/000863 WO2001054676A2 (en) | 2000-01-28 | 2001-01-26 | Formulations for states of dehydration |
Country Status (3)
| Country | Link |
|---|---|
| AU (1) | AU2001244108A1 (en) |
| DE (1) | DE10003835A1 (en) |
| WO (1) | WO2001054676A2 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1688139A1 (en) * | 2000-09-14 | 2006-08-09 | Board of Regents of the University of Nebraska | Creatine ester pronutrient compounds and formulations |
| US20030212136A1 (en) | 2001-09-14 | 2003-11-13 | Vennerstrom Jonathan L. | Creatine ester pronutrient compounds and formulations |
| DE10215007A1 (en) * | 2002-04-05 | 2003-10-16 | Degussa Bioactives Deutschland | Use of creatine pyruvate to increase endurance during high-intensity physical interval workouts |
| DE102004009962A1 (en) * | 2004-03-01 | 2005-09-22 | Degussa Ag | Use of guanidine compounds as physiological restorative in the form of nutritional supplements, feed additives, in cosmetic preparations and as plant strengthening agents |
| BRPI0511842B1 (en) | 2004-06-09 | 2014-08-12 | Alzchem Trostberg Gmbh | Use of guanidino acetic acid as feed additive |
| DE102007004781A1 (en) | 2007-01-31 | 2008-08-07 | Alzchem Trostberg Gmbh | Use of guanidinoacetic acid (salts) for the preparation of a health-promoting agent |
| US9233099B2 (en) | 2012-01-11 | 2016-01-12 | University Of Cincinnati | Methods of treating cognitive dysfunction by modulating brain energy metabolism |
| BR112020019467A2 (en) | 2018-03-27 | 2020-12-29 | Evonik Operations Gmbh | USE OF GUANIDINOACETIC ACID AND / OR CREATIN IN AQUACULTURE |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991014435A1 (en) * | 1990-03-19 | 1991-10-03 | Brigham And Women's Hospital | Treatment of osmotic disturbance with organic osmolytes |
| US5397786A (en) * | 1993-01-08 | 1995-03-14 | Simone; Charles B. | Rehydration drink |
| WO1998028263A1 (en) * | 1996-12-20 | 1998-07-02 | Skw Trostberg Aktiengesellschaft | Creatine pyruvates and method for their production |
| WO1998038183A1 (en) * | 1997-02-26 | 1998-09-03 | Skw Trostberg Aktiengesellschaft | Creatine-ascorbates, production process |
| DE19929994A1 (en) * | 1998-07-09 | 2000-01-13 | Sueddeutsche Kalkstickstoff | Treatment of skeletal muscle dystrophies and atrophies using creatine |
| WO2000015187A1 (en) * | 1998-09-10 | 2000-03-23 | Skw Trostberg Aktiengesellschaft | Creatine and/or creatine derivatives used as cosmetic preparations containing moisturizers |
| WO2001003325A2 (en) * | 1999-06-30 | 2001-01-11 | Skw Trostberg Aktiengesellschaft | Use of creatine and/or creatine derivatives for treating feelings of ill-health in women |
-
2000
- 2000-01-28 DE DE10003835A patent/DE10003835A1/en not_active Withdrawn
-
2001
- 2001-01-26 AU AU2001244108A patent/AU2001244108A1/en not_active Abandoned
- 2001-01-26 WO PCT/EP2001/000863 patent/WO2001054676A2/en active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991014435A1 (en) * | 1990-03-19 | 1991-10-03 | Brigham And Women's Hospital | Treatment of osmotic disturbance with organic osmolytes |
| US5397786A (en) * | 1993-01-08 | 1995-03-14 | Simone; Charles B. | Rehydration drink |
| WO1998028263A1 (en) * | 1996-12-20 | 1998-07-02 | Skw Trostberg Aktiengesellschaft | Creatine pyruvates and method for their production |
| WO1998038183A1 (en) * | 1997-02-26 | 1998-09-03 | Skw Trostberg Aktiengesellschaft | Creatine-ascorbates, production process |
| DE19929994A1 (en) * | 1998-07-09 | 2000-01-13 | Sueddeutsche Kalkstickstoff | Treatment of skeletal muscle dystrophies and atrophies using creatine |
| WO2000015187A1 (en) * | 1998-09-10 | 2000-03-23 | Skw Trostberg Aktiengesellschaft | Creatine and/or creatine derivatives used as cosmetic preparations containing moisturizers |
| WO2001003325A2 (en) * | 1999-06-30 | 2001-01-11 | Skw Trostberg Aktiengesellschaft | Use of creatine and/or creatine derivatives for treating feelings of ill-health in women |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001054676A2 (en) | 2001-08-02 |
| DE10003835A1 (en) | 2001-08-16 |
| AU2001244108A1 (en) | 2001-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL154888A (en) | Non-aqueous pharmaceutical gel composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid and its use in the manufacture of a medicament for treatment of psoriasis | |
| YU48099A (en) | Composition that involves nutrient and herb and its application | |
| GB2276086A (en) | Pharmaceutical products for curing tumorous diseases and process for preparing same | |
| EP1561464A3 (en) | Use of cyclopamine in the treatment of basal cell carcinoma and other tumors | |
| HUP0204574A3 (en) | Propionic acid derivatives and their use in the treatment of diabetes and obesity, pharmaceutical compositions containing them and their preparation | |
| HRP920632B1 (en) | Oral composition for the treatment of inflammatory bowel deseases | |
| EP1852114A4 (en) | COMPOSITION CONTAINING DIHOMO-(gamma)-LINOLENIC ACID (DGLA) AS THE ACTIVE INGREDIENT | |
| HUP0303566A3 (en) | Pharmaceutical composition containing combination of fenofibrate and coenzyme q10 and its use for the treatment of endothelial dysfunction | |
| CA2373794A1 (en) | Compositions and uses of et743 for treating cancer | |
| EP1637132A4 (en) | External preparation for athlete´s foot treatment | |
| GB2456475A (en) | Composition for the treatment of skin conditions | |
| WO2001054676A3 (en) | Formulations for states of dehydration | |
| TW200740424A (en) | Taste masking dosage form | |
| WO2006138571A3 (en) | Composition and methods for treating complications associated with ingestion of a medicinal, chemical or biological substance | |
| HUP0302538A3 (en) | 3,7-diazabicyclo[3.3.0]oczanes and their use in the treatment of cardiac arrhythmias, process for their preparation and pharmaceutical compositions containing them | |
| WO2002053090A3 (en) | Medicinal association of a biguanine (metformin) and arginine | |
| GEP20043202B (en) | Resorcinol Derivatives | |
| WO2001074365A3 (en) | An efficacious dosage regimen of galantamine that reduces side effects | |
| HUP0303977A3 (en) | Procedure for the preparation of pure phosphatides and their use in the cosmetic, pharmaceutical nad alimentary fields | |
| AU7862401A (en) | Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer | |
| NZ528164A (en) | Use of flumazenil to produce a medicament for the treatment of ***e dependency | |
| HUP9802897A3 (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient | |
| WO2002017952A3 (en) | Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma | |
| WO2000064421A3 (en) | Use of n-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients | |
| CA2376033A1 (en) | Use of l-carnitine and its alkanoyl derivatives for the preparation of a medicament useful for the treatment of patients suffering from diabetic and/or dysmetabolic nephropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |